Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1986 Dec;89(4):703–711. doi: 10.1111/j.1476-5381.1986.tb11174.x

Vasodilator actions of TRK-100, a new prostaglandin I2 analogue.

T Akiba, M Miyazaki, N Toda
PMCID: PMC1917240  PMID: 3101928

Abstract

TRK-100, a stable analogue of prostaglandin I2 (PGI2), relaxed isolated arteries of the dog precontracted with PGF2 alpha or K+; the relaxation was in the order of mesenteric and renal greater than coronary and femoral greater than basilar and middle cerebral arteries. The relaxation by TRK-100 was not affected by treatment with atropine, propranolol, cimetidine, aminophylline, and indomethacin, but was suppressed by diphloretin phosphate, a prostaglandin antagonist. Treatment with TRK-100 attenuated the contraction induced by PGF2 alpha and Ca2+ in mesenteric and basilar arteries previously exposed to Ca2+-free medium, but did not significantly alter the contractile response to Ca2+ in the arteries exposed to Ca2+-free medium and depolarized by excess K+. TRK-100 and nitroglycerin relaxed isolated mesenteric arteries to a similar extent; however, when continuously infused into mesenteric arteries in anaesthetized dogs, TRK-100 produced greater vasodilatation than nitroglycerin. It is concluded that TRK-100 relaxes dog mesenteric and renal arteries more than cerebral arteries; the relaxation appears to derive from interference with the release of Ca2+ from intracellular stores and with the transmembrane Ca2+ influx through a receptor-operated channel. TRK-100 may vasodilate large and small mesenteric arteries and resistance vessels to a similar extent, whereas nitroglycerin preferentially dilates the large artery.

Full text

PDF
703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adaikan P. G., Kottegoda S. R., Lau L. C., Tai M. Y., Karim S. M. Inhibition of platelet aggregation and reversal of vasopressin-induced ECG changes by a carboprostacyclin analogue, ONO 41483, in primates. Prostaglandins Leukot Med. 1982 Sep;9(3):307–320. doi: 10.1016/s0262-1746(82)80018-8. [DOI] [PubMed] [Google Scholar]
  2. Furchgott R. F. Role of endothelium in responses of vascular smooth muscle. Circ Res. 1983 Nov;53(5):557–573. doi: 10.1161/01.res.53.5.557. [DOI] [PubMed] [Google Scholar]
  3. Levenson J. A., Simon A. C., Safar M. E. Vasodilatation of small and large arteries in hypertension. J Cardiovasc Pharmacol. 1985;7 (Suppl 2):S115–S120. doi: 10.1097/00005344-198507002-00022. [DOI] [PubMed] [Google Scholar]
  4. Schölkens B. A., Gehring D., Jung W. The orally active thia-imino-prostacyclin Hoe 892: antiaggregatory and cardiovascular activities. Prostaglandins Leukot Med. 1983 Mar;10(3):231–256. doi: 10.1016/0262-1746(82)90080-4. [DOI] [PubMed] [Google Scholar]
  5. Schölkens B. A., Scholtholt J., Becker R., Jung W., Speth O. Influence of prostacyclin on regional blood flow distribution in anesthetized dogs. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):244–254. [PubMed] [Google Scholar]
  6. Sim A. K., McCraw A. P., Cleland M. E., Nishio S., Umetsu T. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneimittelforschung. 1985;35(12):1816–1818. [PubMed] [Google Scholar]
  7. Skuballa W., Vorbrüggen H. Synthesis of ciloprost (ZK 36 374): a chemically stable and biologically potent prostacyclin analog. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:299–305. [PubMed] [Google Scholar]
  8. Toda N., Hatano Y., Hayashi S. Modifications by stretches of the mechanical response of isolated cerebral and extracerebral arteries to vasoactive agents. Pflugers Arch. 1978 Apr 25;374(1):73–77. doi: 10.1007/BF00585699. [DOI] [PubMed] [Google Scholar]
  9. Toda N., Nakajima S., Miyazaki M., Ueda M. Vasodilatation induced by pinacidil in dogs. Comparison with hydralazine and nifedipine. J Cardiovasc Pharmacol. 1985 Nov-Dec;7(6):1118–1126. doi: 10.1097/00005344-198511000-00017. [DOI] [PubMed] [Google Scholar]
  10. Toda N. Potentiation by ouabain of the response to vasoconstrictor agents of isolated dog cerebral and mesenteric arteries soaked in Ca2+-free media. J Cardiovasc Pharmacol. 1982 May-Jun;4(3):469–474. doi: 10.1097/00005344-198205000-00019. [DOI] [PubMed] [Google Scholar]
  11. Toda N. Responses of human, monkey and dog coronary arteries in vitro to carbocyclic thromboxane A2 and vasodilators. Br J Pharmacol. 1984 Oct;83(2):399–408. doi: 10.1111/j.1476-5381.1984.tb16500.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Whittle B. J., Moncada S., Whiting F., Vane J. R. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins. 1980 Apr;19(4):605–627. doi: 10.1016/s0090-6980(80)80010-4. [DOI] [PubMed] [Google Scholar]
  13. Yui Y., Takatsu Y., Hattori R., Kawai C., Osaki Y., Yohida T. A new stable prostacyclin analogue OP41483 (15-cyclopentyl-omega-pentanor-5(E)-carbacyclin). Jpn Circ J. 1985 Jun;49(6):571–575. doi: 10.1253/jcj.49.571. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES